Intramuscular anti-D in chronic immune thrombocytopenia children with severe thrombocytopenia.

Abstract

Nine patients with chronic immune thrombocytopenia and platelet counts <20 × 10(9) /L, with a median age of 7.8 (3.8-15.5) years, received three phases of 10 mcg/kg/dose of intramuscular anti-D. Phase 1 was anti-D daily for 5 days, followed by phase 2, anti-D weekly for 12 weeks and withheld when platelet counts ≥ 20 × 10(9) /L, and then phase 3 was anti-D once every 2 weeks for 24 weeks. According to the International Working Group criteria, in phase 1, 66.7% of patients responded to the treatment. In phases 2 and 3, 11.1% (0-41.7%) and 7.7% (0-33.3%) of total episodes of follow up, respectively, responded to the treatment. Therefore, intramuscular anti-D given at a dose of 10 mcg/kg for 5 days is an alternative method to raise platelet counts in chronic immune thrombocytopenia children with severe thrombocytopenia where the intravenous form of anti-D is not available.

• Authors: Nongnuch Sirachainan, Usanarat Anurathapan, Ampaiwan Chuansumrit, Duantida Songdej, Pakawan Wongwerawattanakoon, Sakara Hutspardol, Pimpun Kitpoka
• Journal: Pediatrics international : official journal of the Japan Pediatric Society (Pediatr Int) Vol. 55 Issue 6 Pg. e146-8 (Dec 2013) ISSN: 1442-200X [Electronic] Australia
• PMID: 24330299 (Publication Type: Journal Article)
• Copyright: © 2013 The Authors. Pediatrics International © 2013 Japan Pediatric Society.

Chemical References

• Isoantibodies
• RHO(D) antibody
• Rho(D) Immune Globulin

Topics

• Adolescent
• Child
• Child, Preschool
• Female
• Humans
• Injections, Intramuscular
• Isoantibodies (administration & dosage)
• Male
• Purpura, Thrombocytopenic, Idiopathic (drug therapy)
• Rho(D) Immune Globulin
• Severity of Illness Index